Sangui Biotech International Inc (SGBI) Financial Statements (2024 and earlier)

Company Profile

Business Address 352 SOUTH 200 WEST
FARMINGTON, UT 84025
State of Incorp. CO
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2023
MRQ
12/31/2022
MRQ
6/30/2022
6/30/2021
6/30/2020
6/30/2019
6/30/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments93030152721
Cash and cash equivalents93030152721
Receivables 1723231735 
Prepaid expense14121213921
Other undisclosed current assets4223760
Total current assets:4468674979102
Noncurrent Assets
Property, plant and equipment0012  
Other undisclosed noncurrent assets 55636675  
Total noncurrent assets:55636777  
TOTAL ASSETS:9913113412579102
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities      
Accrued liabilities      
Debt724708753619478 
Due to related parties 8372624228 
Other undisclosed current liabilities184156140131164453
Total current liabilities:991936955791671453
Noncurrent Liabilities
Long-term debt and lease obligation44905564  
Long-term debt, excluding current maturities4449    
Liabilities, other than long-term debt34     
Operating lease, liability34415564
Other undisclosed noncurrent liabilities  (41)(55)(64)  
Total noncurrent liabilities:78905564  
Total liabilities:1,0691,0261,009855671453
Equity
Equity, attributable to parent, including:(315)(239)(224)(83)49(351)
Common stock33,12533,12533,08833,02832,96732,864
Treasury stock, value(19)(19)(19)(19)(19)19
Additional paid in capital4,5134,5134,5134,5134,5134,513
Accumulated other comprehensive income1009790929193
Accumulated deficit(38,034)(37,955)(37,895)(37,696)(37,504)(37,180)
Other undisclosed equity, attributable to parent      (661)
Equity, attributable to noncontrolling interest(655)(656)(652)(647)(641) 
Total equity:(970)(895)(875)(730)(592)(351)
TOTAL LIABILITIES AND EQUITY:9913113412579102

Income Statement (P&L) ($ in thousands)

3/31/2023
TTM
12/31/2022
TTM
6/30/2022
6/30/2021
6/30/2020
6/30/2019
6/30/2018
Revenues806966298877
Cost of revenue
(Cost of Goods and Services Sold)
      (0)
Gross profit:806966298877
Operating expenses(200)(209)(217)(210)(426)(285)
Operating loss:(120)(139)(151)(181)(338)(208)
Nonoperating income (expense)1676(53)(17)(5) 
Gain (loss), foreign currency transaction, before tax41100(35)47 
Interest and debt expense(28)(23)(18)(14)(12)8
Loss from continuing operations before equity method investments, income taxes:(132)(86)(222)(213)(354)(200)
Other undisclosed loss from continuing operations before income taxes      (16)
Loss from continuing operations:(132)(86)(222)(213)(354)(216)
Income (loss) before gain (loss) on sale of properties:(24)(86)(222)(213)(354)(216)
Other undisclosed net income2823181412 
Net loss:(104)(63)(204)(199)(343)(216)
Other undisclosed net income (loss) attributable to parent245619(29)
Net loss available to common stockholders, diluted:(101)(59)(199)(193)(324)(245)

Comprehensive Income ($ in thousands)

3/31/2023
TTM
12/31/2022
TTM
6/30/2022
6/30/2021
6/30/2020
6/30/2019
6/30/2018
Net loss:(104)(63)(204)(199)(343)(216)
Other comprehensive income9356206198344 
Comprehensive income (loss), net of tax, attributable to parent:(11)(7)2(0)1(216)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: